A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation

NCT07259590 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

126

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Cancer
PDAC
CRC (Colorectal Cancer)

Interventions

COMBINATION_PRODUCT: GFH375
COMBINATION_PRODUCT: GFH375

Sponsor

Genfleet Therapeutics (Shanghai) Inc.